Recently announced positive results for second cohort of Phase 2 clinical trial of ZGN-1061 Company is currently in the formal regulatory process related to the clinical hold for ZGN-1061; Update still anticipated in Q2 2019 PATH for PWS study continues enrollment with strong support from PWS community BOSTON, May 09, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, today reported its first quarter 2019 operating and financial results. "Since our last update, we have continued to concentrate on addressing the FDA's comments on the ZGN-1061 IND clinical hold.